FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3211878598> ?p ?o ?g. }

• W3211878598 endingPage "2304" @default.
• W3211878598 startingPage "2304" @default.
• W3211878598 abstract "Abstract INTRODUCTION Children with Down Syndrome (DS) and B-lymphoblastic leukemia (B-ALL) are at an increased risk of both relapse and treatment-related mortality, compared to those without DS. On COG study AALL1731 for de novo B-ALL, patients with DS and higher risk features (DS-High) are non-randomly treated with a regimen replacing intensive elements of conventional chemotherapy with three 28-day cycles of blinatumomab, with the combined goals of reducing toxicity and enhancing anti-leukemic efficacy. The DS-High group includes all NCI high risk (HR) patients; NCI standard risk (SR) patients with end-induction minimal residual disease positivity (&gt;0.01%), unfavorable cytogenetics, CNS3 status, steroid pre-treatment, neutral cytogenetics with CNS2 status, or testicular disease. Neurotoxicity is a known risk of blinatumomab, with an incidence of 4% in block 1 and 1% in block 2 among pediatric patients with relapsed ALL (Brown et al, JAMA 2021). However, the specific risk in patients with DS has not been described to date. Here, we provide an early report of increased seizure incidence associated with blinatumomab in older DS-High patients enrolled on AALL1731 to date. METHODS We reviewed seizure incidence among patients with DS enrolled on AALL1731 from June 2019 to June 2021 who had proceeded to receive blinatumomab. Blinatumomab was administered at a dose of 15 mcg/m 2/day, using dexamethasone pre-medication in cycle 1. Infusions were interrupted for seizures, with resumption at 5 mcg/m 2/d permitted following full resolution for grade 1-3 seizures. RESULTS Among DS NCI HR patients, 8 of 47 (17%) had a seizure during blinatumomab infusion (Table 1). All 8 seizures occurred in patients over 10 years old. Six of the 8 seizures occurred in the first cycle of blinatumomab, most in the first 3 days of the infusion. Four had concomitant fever or cytokine release syndrome. Seizures were grade 2 (n=2) or grade 3 (n=6), and all resolved with full neurologic recovery. Of the 8 patients, 5 elected to resume blinatumomab; no further seizures occurred in these patients. There was no indication of increased seizure risk among NCI SR DS-High patients (1 seizure among 11 patients), or among DS or non-DS patients receiving blinatumomab on other study strata (0 of 7 DS SR-Avg; 1 of 146 non-DS SR-Avg; and 2 of 120 non-DS SR-High). CONCLUSIONS The incidence of seizures associated with blinatumomab in DS-ALL patients older than 10 years appears higher than previously reported in children without DS. The majority of seizures occurred within the first 3 days, all fully resolved with no sequelae, and no patient who resumed blinatumomab infusion at a lower rate experienced further seizures. Seizure prophylaxis may be advisable in DS patients while receiving blinatumomab, particularly those &gt;10 years of age. Further follow-up and a larger sample size are needed to confirm incidence and identify risk factors predisposing DS patients to neurologic toxicity. Figure 1 Figure 1. Disclosures Li: Novartis Canada: Membership on an entity's Board of Directors or advisory committees. Raetz: Pfizer: Research Funding; Celgene: Other: DSMB member. Loh: MediSix therapeutics: Membership on an entity's Board of Directors or advisory committees. Gupta: Jazz Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees. Rau: Jazz Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Advisory Board; AbbVie Pharmaceuticals: Other: Spouse is employee and stock holder; Servier Pharmaceuticals: Consultancy. OffLabel Disclosure: This trial includes the use of blinatumomab in combination with chemotherapy for treatment of de novo B-lymphoblastic leukemia." @default.
• W3211878598 created "2021-11-22" @default.
• W3211878598 creator A5001743219 @default.
• W3211878598 creator A5010578315 @default.
• W3211878598 creator A5010840699 @default.
• W3211878598 creator A5024573751 @default.
• W3211878598 creator A5025004880 @default.
• W3211878598 creator A5031246149 @default.
• W3211878598 creator A5033126546 @default.
• W3211878598 creator A5036550103 @default.
• W3211878598 creator A5051652369 @default.
• W3211878598 creator A5060686708 @default.
• W3211878598 creator A5061945652 @default.
• W3211878598 creator A5074833289 @default.
• W3211878598 creator A5085010022 @default.
• W3211878598 date "2021-11-05" @default.
• W3211878598 modified "2023-10-16" @default.
• W3211878598 title "Blinatumomab Associated Seizure Risk in Patients with Down Syndrome and B-Lymphoblastic Leukemia: An Interim Report from Children's Oncology Group (COG) Study AALL1731" @default.
• W3211878598 doi "https://doi.org/10.1182/blood-2021-148967" @default.
• W3211878598 hasPublicationYear "2021" @default.
• W3211878598 type Work @default.
• W3211878598 sameAs 3211878598 @default.
• W3211878598 citedByCount "7" @default.
• W3211878598 countsByYear W32118785982022 @default.
• W3211878598 countsByYear W32118785982023 @default.
• W3211878598 crossrefType "journal-article" @default.
• W3211878598 hasAuthorship W3211878598A5001743219 @default.
• W3211878598 hasAuthorship W3211878598A5010578315 @default.
• W3211878598 hasAuthorship W3211878598A5010840699 @default.
• W3211878598 hasAuthorship W3211878598A5024573751 @default.
• W3211878598 hasAuthorship W3211878598A5025004880 @default.
• W3211878598 hasAuthorship W3211878598A5031246149 @default.
• W3211878598 hasAuthorship W3211878598A5033126546 @default.
• W3211878598 hasAuthorship W3211878598A5036550103 @default.
• W3211878598 hasAuthorship W3211878598A5051652369 @default.
• W3211878598 hasAuthorship W3211878598A5060686708 @default.
• W3211878598 hasAuthorship W3211878598A5061945652 @default.
• W3211878598 hasAuthorship W3211878598A5074833289 @default.
• W3211878598 hasAuthorship W3211878598A5085010022 @default.
• W3211878598 hasBestOaLocation W32118785981 @default.
• W3211878598 hasConcept C120665830 @default.
• W3211878598 hasConcept C121332964 @default.
• W3211878598 hasConcept C126322002 @default.
• W3211878598 hasConcept C143998085 @default.
• W3211878598 hasConcept C187212893 @default.
• W3211878598 hasConcept C2778020697 @default.
• W3211878598 hasConcept C2778461978 @default.
• W3211878598 hasConcept C2781107101 @default.
• W3211878598 hasConcept C2909962599 @default.
• W3211878598 hasConcept C535046627 @default.
• W3211878598 hasConcept C61511704 @default.
• W3211878598 hasConcept C61943457 @default.
• W3211878598 hasConcept C71924100 @default.
• W3211878598 hasConceptScore W3211878598C120665830 @default.
• W3211878598 hasConceptScore W3211878598C121332964 @default.
• W3211878598 hasConceptScore W3211878598C126322002 @default.
• W3211878598 hasConceptScore W3211878598C143998085 @default.
• W3211878598 hasConceptScore W3211878598C187212893 @default.
• W3211878598 hasConceptScore W3211878598C2778020697 @default.
• W3211878598 hasConceptScore W3211878598C2778461978 @default.
• W3211878598 hasConceptScore W3211878598C2781107101 @default.
• W3211878598 hasConceptScore W3211878598C2909962599 @default.
• W3211878598 hasConceptScore W3211878598C535046627 @default.
• W3211878598 hasConceptScore W3211878598C61511704 @default.
• W3211878598 hasConceptScore W3211878598C61943457 @default.
• W3211878598 hasConceptScore W3211878598C71924100 @default.
• W3211878598 hasIssue "Supplement 1" @default.
• W3211878598 hasLocation W32118785981 @default.
• W3211878598 hasOpenAccess W3211878598 @default.
• W3211878598 hasPrimaryLocation W32118785981 @default.
• W3211878598 hasRelatedWork W1969388105 @default.
• W3211878598 hasRelatedWork W2055132182 @default.
• W3211878598 hasRelatedWork W2077163773 @default.
• W3211878598 hasRelatedWork W2127866346 @default.
• W3211878598 hasRelatedWork W2265868850 @default.
• W3211878598 hasRelatedWork W2275480158 @default.
• W3211878598 hasRelatedWork W2919460009 @default.
• W3211878598 hasRelatedWork W3213762894 @default.
• W3211878598 hasRelatedWork W4238089809 @default.
• W3211878598 hasRelatedWork W2531692626 @default.
• W3211878598 hasVolume "138" @default.
• W3211878598 isParatext "false" @default.
• W3211878598 isRetracted "false" @default.
• W3211878598 magId "3211878598" @default.
• W3211878598 workType "article" @default.